In-vitro and in-vivo evaluations of cytochrome P450 1A2 interactions with nuciferine

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 5, 2010, Pages 658-662

  Hu, Liwei ^a   Xu, Wen ^b   Zhang, Xi ^a   Su, Juan ^a   Liu, Xinru ^a   Li, Haiyun ^a   Zhang, Weidong ^a,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cytochrome CYP1A2; Herb drug interactions; Nuciferine; Phenacetin

Indexed keywords

ALKALOID; CYTOCHROME P450 1A2; NUCIFERINE; PHENACETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT;

EID: 77952783140     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.05.0015     Document Type: Article

References (29)

1. Kelly JP et al. Recent trends in use of herbal and other natural products. Arch Intern Med 2005 165 : 281 286.
2. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St John's wort) after organ transplantation. Am J Kidney Dis 2001 38 : 1105 1107.
3. Schwarz UI et al. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003 55 : 112 113.
4. Ernst E. Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol 2000 56 : 523 524.
5. Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2004 19 : 1 116.
6. Magee KA. Herbal therapy: a review of potential health risks and medicinal interactions. Orthod Craniofac Res 2005 8 : 60 74.
7. Pharmacopoeia Committee of P.R. China, eds. Chinese Pharmacopoeia.
8. Duggan AW et al. Effect of nuciferine on the chemical excitation of Renshaw cells in the rat. Arch Int Pharmacodyn Ther 1973 204 : 147 149.
9. Du LJ et al. Studies on the active components in the leaf of Nelumbo nucifera and black soybean and their mixture with blood lipid regulating effect. Chin Tradit Herbal Drugs 2000 31 : 526 528.
10. Kashiwada Y et al. Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure-activity correlations with related alkaloids. Bioorg Med Chem 2005 13 : 443 448.
11. Guengerich F. Cytochrome P450 enzymes. Am Sci 1993 81 : 440 447.
12. Faber MS et al. Assessment of CYP1A2 activity in clinical practice: why, how, and when Basic Clin Pharmacol Toxicol 2005 97 : 125 134.
13. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000 294 : 88 95.
14. von Moltke LL et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004 56 : 1039 1044.
15. Cermak R, Wolffram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab 2006 7 : 729 744.
16. Zhang SY et al. Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats. J Chromatogr B 2008 871 : 78 89.
17. Kessler RC et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001 135 : 262 268.
18. Kaufman DW et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002 287 : 337 344.
19. Zhou HH et al. "Cocktail" approaches and strategies in drug development: valuable tool or flawed science J Clin Pharmacol 2004 44 : 120 134.
20. Welfare MR et al. The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects. Br J Clin Pharmacol 2000 49 : 240 243.
21. Tantcheva-Poor I et al. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999 9 : 131 144.
22. Tolonen A et al. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 2007 42 : 960 966.
23. Yao M et al. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal 2007 44 : 211 223.
24. Boobis AR et al. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res 1994 54 : 89 94.
25. Beresford AP et al. Cytochrome P4501A (CYP1A) induction in rat and man by the benzodioxino derivative, fluparoxan. Xenobiotica 1997 27 : 159 173.
26. Zhu Q et al. Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica 2009 39 : 293 301.
27. Cui ZF et al. Phenacetin O-deethylation in extrahepatic tissues of the rats. Eur J Drug Metab Pharmacokinet 2002 27 : 107 111.
28. Levy G, Koysooko R. Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children. J Pediatr 1975 86 : 789 793.
29. Hasegawa T et al. Effect of mequitazine on the pharmacokinetics of theophylline in asthmatic patients. Eur J Clin Pharmacol 1990 38 : 255 258.